CDSCO Revises Public Hearing Schedule

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-05-11 11:30 GMT | Update On 2025-05-11 11:30 GMT

New Delhi: Through a recent notice, the Central Drugs Standard Control Organisation (CDSCO), the Directorate General of Health Services,the Ministry of Health and Family Welfare, has revised the public hearing schedule at their Public Relations Office (PRO) in the interest of strengthening regulatory guidance for stakeholders and innovators.

This revision builds upon earlier notices dated 04.10.2019, 10.12.2021, and 22.02.2022, aiming to improve access and streamline regulatory consultations.

The notice mentioned, "The schedule is revised in the public interest."

As per the revised schedule, the PRO at CDSCO (HQ), New Delhi, will be operational every day except holidays from 4:00 PM to 6:00 PM in the following manner to strengthen the process of regulatory guidance to stakeholders and innovators. However, it is further noted that on Monday, stakeholders may visit from 3:00 PM till 6:00 PM.

Day	Name of Division
Monday	Medical Device & IVD (3:00 PM – 6:00 PM)
Tuesday	New Drug, IND, SND & International Cell
Wednesday	Import & Registration, FDC & LVP
Thursday	Biologicals, Blood Products/Blood Centre & Ayush
Friday	BA/BE, Ethics Committee, GCT, CRO Registration, CDAC/IT Cell, Veterinary & Cosmetics

In addition to the above, the notice stated that all stakeholders may avail themselves of the facilities as per their requirements.

Also Read:CDSCO Panel approves Eli Lilly proposal to Increase patients number from India 37 to 57 for LY3871801 study

To view the official notice, click the link below:

https://medicaldialogues.in/pdf_upload/public-notice-on-pro-schedule-286363.pdf

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CDSCO Revises Public Hearing Schedule

Similar News

Wockhardt Misses NPPA Clearance for Nafithromycin, Faces Questions on Patent Validity

Ajanta Pharma Told to Revise BE Study Protocol for Cilnidipine, Metoprolol FDC

Zydus Gets CDSCO Panel Nod to Market Sodium Chloride Nebuliser Solution

SC doors knocked for child deaths linked to contaminated cough syrup, CBI probe demanded

AstraZeneca Pharma India bags CDSCO nod for expanded use of Trastuzumab Deruxtecan in HER2-Positive Solid Tumors

Coldrif Cough Syrup banned in Punjab amid child deaths

Contaminated cough syrup tragedy: NHRC steps in, demands investigation

DoP identifies 11,100 Jan Aushadhi Kendras across India as Outdoor Cleaning Sites